States reach major settlement with family behind OxyContin


This recording was made using enhanced software.

Summary

Purdue Pharma settlement

All 50 U.S. states, Washington, D.C., and four U.S. territories have agreed to a $7.4 billion settlement with Purdue Pharma, the manufacturer of OxyContin.

Accountability measures

The settlement requires the Sackler family to give up ownership of Purdue Pharma and permanently bars them from the manufacturing, sale, or marketing of opioids in the United States.

Opioid epidemic impact

From 1999 to 2022, nearly 727,000 people died from opioid overdoses in the United States.


Full story

All 50 U.S. states, Washington, D.C., and four U.S. territories have agreed to a $7.4 billion settlement with Purdue Pharma, the company behind OxyContin. The states argued the Sackler family, who own Purdue Pharma, fueled the opioid epidemic by aggressively marketing the addictive drug.

Purdue Pharma lawsuit

The agreement, signed by 55 attorneys general, ends years of legal battles dating back to 2018 when six states first sued Purdue Pharma and the Sackler family. The lawsuits accused the Sacklers of aggressively marketing OxyContin despite its addictive potential.

As part of the new deal, the Sackler family will relinquish ownership of Purdue Pharma. They are also permanently barred from manufacturing, selling or marketing opioids in the United States.

California Attorney General Rob Bonta praised the settlement for providing accountability and help for people with an addiction.

“By holding Purdue Pharma and the Sackler family accountable for their role in fueling the opioid epidemic, we’re bringing much-needed funds for addiction treatment, prevention, and recovery to those impacted by this crisis,” he said in a news release.

The money will go to supporting opioid addiction treatment, prevention, and recovery programs, as well as some victims. Purdue Pharma’s future will be determined by a board of trustees selected by participating states. The company will still be prevented from lobbying or marketing opioids.

This settlement will have to be approved by a federal bankruptcy court. In 2024, the Supreme Court rejected a $6 billion Purdue Pharma bankruptcy deal. It would have protected the Sackler family if Purdue Pharma had filed for bankruptcy.

The court ruled the bankruptcy code does not authorize courts to shield third parties, like the Sacklers, from lawsuits without creditor consent. Purdue then filed the new plan for the $7.4 billion back in March.

“We and our creditors have worked tirelessly in mediation to build consensus and negotiate a settlement that will increase the total value provided to victims and communities, put billions of dollars to work on day one, and serve the public good,” Purdue Board Chairman Steve Miller said following the filing.

If the bankruptcy court approves, local governments across the country will be asked to join the settlement. There will be a hearing for local officials on Wednesday, June 16.

The Sacklers continue to maintain they did nothing wrong.

Opioid epidemic

The opioid epidemic is often said to have come in three waves, beginning in the 1990s with increasing overdose deaths from prescription opioids like OxyContin. The second wave began around 2010, with people struggling to get prescriptions and turning to heroin.

The third wave began around 2013 with significant increases in overdose deaths from synthetic opioids such as fentanyl.

From 1999 to 2022, nearly 727,000 people have died from opioid overdoses.

Chris Field (Executive Editor) contributed to this report.
Tags: , ,

Why this story matters

A $7.4 billion settlement involving Purdue Pharma and the Sackler family addresses the company’s role in the opioid epidemic and aims to provide funds for addiction treatment and prevention nationwide as well as provide accountability for the opioid epidemic.

Opioid accountability

The settlement requires Purdue Pharma and the Sackler family to relinquish ownership and involvement in opioid production, reflecting efforts to hold those linked to the opioid epidemic responsible, as noted by California Attorney General Rob Bonta and others.

Addiction treatment funding

According to the announcement, the settlement funds are designated to support addiction treatment, prevention, and recovery, aiming to assist victims and communities affected by opioid misuse.

Legal and regulatory outcomes

The agreement follows years of litigation, a Supreme Court decision limiting legal protections for the Sacklers, and ongoing judicial review, highlighting the broader context of legal oversight in addressing public health crises.

Timeline

  • Purdue Pharma and the Sackler family have agreed to pay over $7 billion for their role in the opioid crisis.
    AP Images
    Business
    Jan 23

    Purdue Pharma, Sackler family agree on historic settlement over OxyContin

    Purdue Pharma and the Sackler family have agreed to pay more than $7 billion to settle claims over their role in fueling the U.S. opioid epidemic. This settlement is the latest chapter in a legal battle over the company’s widely prescribed painkiller, OxyContin. Experts describe it as a gateway drug to harder substances like heroin….

  • The Supreme Court ruled that the Sackler family can't receive immunity from opioid lawsuits under the bankruptcy deal with Purdue Pharma.
    Getty Images
    Politics
    Jun 27

    SCOTUS rules Sackler family not protected under Purdue bankruptcy case

    The Supreme Court ruled Thursday, June 27, that the Sackler family — which owned Purdue Pharma and marketed the opioid pain reliever OxyContin — is not immune from lawsuits. The high court said the deal made with a bankruptcy court to avoid liability is improper.  The 5-4 decision was ideologically mixed. The opinion was written…

Timeline

  • Purdue Pharma and the Sackler family have agreed to pay over $7 billion for their role in the opioid crisis.
    AP Images
    Business
    Jan 23

    Purdue Pharma, Sackler family agree on historic settlement over OxyContin

    Purdue Pharma and the Sackler family have agreed to pay more than $7 billion to settle claims over their role in fueling the U.S. opioid epidemic. This settlement is the latest chapter in a legal battle over the company’s widely prescribed painkiller, OxyContin. Experts describe it as a gateway drug to harder substances like heroin….

  • The Supreme Court ruled that the Sackler family can't receive immunity from opioid lawsuits under the bankruptcy deal with Purdue Pharma.
    Getty Images
    Politics
    Jun 27

    SCOTUS rules Sackler family not protected under Purdue bankruptcy case

    The Supreme Court ruled Thursday, June 27, that the Sackler family — which owned Purdue Pharma and marketed the opioid pain reliever OxyContin — is not immune from lawsuits. The high court said the deal made with a bankruptcy court to avoid liability is improper.  The 5-4 decision was ideologically mixed. The opinion was written…